Photoluminescence Dosimetry:  Progress and Present State of Art

Piesch, E.; Burgkhardt, B.; Vilgis, M.

doi:10.1093/oxfordjournals.rpd.a080796

Cited by 35 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A radio-photoluminescence glass dosimeter (RPLGD) is newly introduced, as a substitution of the themoluminescence dosimeter (TLD) or other, which was commonly used for in-vivo measurement [23-27]. In this study, we used commercially available RPLGD (GD-302M, Asahi Techno Glass Co., JAPAN).…”

Section: Methodsmentioning

confidence: 99%

“…An RPLGD measured the absorbed dose by counting the orange light (500 ~ 700 nm) from the dosimeter, when 365 nm of mono-energetic light was exposed on the irradiated dosimeter. RPLGD has relatively good reproducibility at about 1% and low energy dependency, at higher than 200 keV energy [23-27]. In addition, RPLGD has relatively small incident beam angular dependency, and low toxicity inside the human body, compared with a TLD or optically stimulated luminescence dosimeter (OSLD) [28-30].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

et al. 2013

View full text Add to dashboard Cite

PurposeTo compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer.MethodsIMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD).ResultsThe secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63% and 41.59% revealing 88.63% and 41.59% for thyroid, 82.33% and 41.85% for pancreas, 77.97% and 49.41% for bowel, 73.42% and 72.55% for rectum, 74.16% and 81.51% for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased.ConclusionsOED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In this study, we used the high-dose-range mode. The advantages of the RPLGD, in comparison with the TLD, include its good reproducibility (1%) and relatively low energy dependency at energies higher than 200 keV [23][24][25]. Additionally, in comparison with the TLD or OSLD, the RPLGD has a smaller incident-beam-angle dependency and lower toxicity inside the human body [26][27][28][29].…”

Section: Rplgdmentioning

confidence: 99%

Sensitivity of Radio-Photoluminescence Glass Dosimeters to Accumulated Doses

Kim

Sung

Son

et al. 2020

Preprint

View full text Add to dashboard Cite

Background This study investigated the effect of accumulated doses on radio-photoluminescence glass dosimeters (RPLGDs) from measurements involving mega-voltage photons. Methods Forty-five commercially available RPLGDs were irradiated to estimate their dose responses. Photon beams of 6, 10, and 15 MV were irradiated onto the RPLGDs inside a phantom, which were divided into five groups with different doses and energies. Groups 1 and 2 were irradiated at 1, 5, 10, 50, and 100 Gy in a sequential manner; Group 3 was irradiated 10 times with a dose of 10 Gy; and Groups 4 and 5 followed the same method as that of Group 3, but with doses of 50 Gy and 100 Gy, respectively. Results For the annealed Group 1, RPLGD exhibited a linearity response with variance within 5%. For the non-annealed Group 2, readings demonstrated hyperlinearity at 6 MV and 10 MV, and linearity at 15 MV. Following the 100 Gy irradiation, the readings for Group 2 were 118.7 ± 1.9%, 112.2 ± 2.7%, and 101.5 ± 2.3% at 6, 10, and 15 MV, respectively. For Groups 3, 4, and 5, the responsiveness of the RPLGDs gradually decreased as the number of repeated irradiations increased. The percentage readings for the 10th beam irradiation with respect to the readings for the primary beam irradiation were 84.6 ± 1.9%, 87.5 ± 2.4%, and 93.0 ± 3.0% at 6 MV, 10 MV, and 15 MV, respectively. Conclusions The non-annealed RPLGD response to dose was hyperlinear for the 6 MV and 10 MV photon beams but not for the 15 MV photon beam. Additionally, the annealed RPLGD exhibited a fading phenomenon when the measurement was repeated several times and demonstrated a relatively large fading effect at low energies than at high energies.

show abstract

“…A commercially-available radio-photoluminescence glass dosimeter (RPLGD; GD-302M, Asahi Techno Glass Co., JAPAN) [8][9][10] was used in this study. An RPLGD is a colorless and transparent glass rod with a 0.15-cm diameter and a length of 0.85 cm.…”

Section: Calibration Of the Radio-photoluminescence Glass Dosimetermentioning

confidence: 99%

“…A dose estimate for the RPLGD is performed by counting the orange light (500 − 700 nm) from the dosimeter when 365-nm mono-energetic laser was exposed on the irradiated dosimeter. The advantages of the RPLGD compared to the thermoluminescence dosimeter (TLD) include good reproducibility of 1% and relatively low energy dependency at energies higher than 200 keV [8][9][10]. In addition, the RPLGD has a relatively small incident-beam-angle dependency and a low toxicity inside a human body compared to the TLD or the optically-stimulated luminescence dosimeter [11][12][13].…”

Section: Calibration Of the Radio-photoluminescence Glass Dosimetermentioning

confidence: 99%

Risk of a second cancer from scattered radiation in acoustic neuroma treatment

Yoon¹,

Lee²,

Sung³

et al. 2014

Journal of the Korean Physical Society

View full text Add to dashboard Cite

The present study aimed to compare the risk of a secondary cancer from scattered and leakage doses in patients receiving intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic radiosurgery (SRS). Four acoustic neuroma patients were treated with IMRT, VMAT, or SRS. Their excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) of a secondary cancer were estimated using the corresponding secondary doses measured at various organs by using radio-photoluminescence glass dosimeters (RPLGD) placed inside a humanoid phantom. When a prescription dose was delivered in the planning target volume of the 4 patients, the average organ equivalent doses (OED) at the thyroid, lung, liver, bowel, bladder, prostate (or ovary), and rectum were 14.6, 1.7, 0.9, 0.8, 0.6, 0.6, and 0.6 cGy, respectively, for IMRT whereas they were 19.1, 1.8, 2.0, 0.6, 0.4, 0.4, and 0.4 cGy, respectively, for VMAT, and 22.8, 4.6, 1.4, 0.7, 0.5, 0.5, and 0.5 cGy, respectively, for SRS. The OED decreased as the distance from the primary beam increased. The thyroid received the highest OED compared to other organs. A lifetime attributable risk evaluation estimated that more than 0.03% of acoustic neuroma (AN) patients would get radiation-induced cancer within 20 years of receiving radiation therapy. The organ with the highest radiation-induced cancer risk after radiation treatment for AN was the thyroid. We found that the LAR could be increased by the transmitted dose from the primary beam. No modality-specific difference in radiation-induced cancer risk was observed in our study.

show abstract

Photoluminescence Dosimetry: Progress and Present State of Art

Cited by 35 publications

References 0 publications

Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

Sensitivity of Radio-Photoluminescence Glass Dosimeters to Accumulated Doses

Risk of a second cancer from scattered radiation in acoustic neuroma treatment

Contact Info

Product

Resources

About